Knowledge Center

• Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million. • Funding award milestone follows Daré’s announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trial. • DARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatments. • Award reflects Daré’s strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contract support for DARE-HPV, to advance a differentiated pipeline addressing some of the most persistent unmet needs in women’s health.

Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments. DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027.

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women’s Health Week.

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts

DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her

The webcast will be archived and available for replay until April 9, 2026.